- Change of Lymphocyte Subsets of HIV-Infected Asymptomatic Persons Administrated with Korean Red Ginseng
-
Choi BS, Park YK, Kee MK, Cho OH, Lee YW, Shin YO
- KMID: 2204570
- J Korean Soc Virol.
- 1997 Mar;27(1):97-104.
For 16 years after the finding of HIV as an agent of AIDS in 1981, HIV therapeutic drugs of reverse transcriptase inhibitors (AZT, ddI, ddC, d4T) and protease inhibitors have... -
- CITED
-
- Close
- SHARE
-
- Close
- Antiviral effect and safety of triple combination therapy in human immunodeficiency virus (HIV)-infected persons
-
Hong SK, Park YS, Cho JH, Roh HJ, Kim HY, Chang KH, Song YG, Kim JM
- KMID: 2080763
- Korean J Med.
- 2000 May;58(5):582-589.
BACKGROUND: Antiretroviral combination therapy with one protease inhibitor and two reverse transcriptase inhibitors is profoundly suppressive of HIV replication. To determine the efficacy and safety of the triple combination therapy in persons... -
- CITED
-
- Close
- SHARE
-
- Close
- Regional Experience of Abacavir: Valuable but Still has Unanswered Question
-
Bang JH
- KMID: 2391434
- Infect Chemother.
- 2017 Sep;49(3):241-242.
- doi: 10.3947/ic.2017.49.3.241
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Metabolic Complications in Korean HIV/AIDS Patients Receiving Highly Active Anti-retroviral Therapy
-
Choe YJ, Park SW, Kim HB, Park WB, Lee KD, Oh MD, Choe KW
- KMID: 2285117
- Infect Chemother.
- 2004 Aug;36(4):197-206.
BACKGROUND: Since the introduction of HAART (Highly Active Anti-Retroviral Therapy), metabolic com- plications have been reported with varying prevalence. We performed a retrospective study to evaluate the incidence and risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Human Monoclonal Antibody Inhibiting Reverse Transcriptase Activity of Hepatitis B Virus Polymerase Protein
-
Park SJ, Seol SY, Jee SR, Park ET, Lee YJ, Lee SH, Chung JM, Cho HD, Jeong YJ, Choi IH, Park SG
- KMID: 935184
- Korean J Gastroenterol.
- 2007 Feb;49(2):85-92.
BACKGROUND/AIMS: To develop a novel treatment method for hepatitis B virus (HBV) infection, we aimed to make a human monoclonal antibody inhibiting reverse transcriptase (RT) activity of P protein which... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials
-
Choi JY, Sungkanuparph S, Anekthananon T, Sax P, DeJesus E, Edelstein , Nelson M, DeMorin J, Liu HC, Swamy R, Bahn J, Hwang S, Yang SY, Ng C, Piontkowsky D
- KMID: 2466435
- Infect Chemother.
- 2016 Sep;48(3):219-224.
- doi: 10.3947/ic.2016.48.3.219
The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) were analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naïve and ART-experienced Asian subjects... -
- CITED
-
- Close
- SHARE
-
- Close
- Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus
-
Lee SA, Kim SW, Chang HH, Jung H, Kim Y, Hwang S, Kim S, Park HK, Lee JM
- KMID: 2420909
- Infect Chemother.
- 2018 Sep;50(3):252-262.
- doi: 10.3947/ic.2018.50.3.252
BACKGROUND: Dual regimen with dolutegravir plus cobicistat-boosted darunavir (DTG/DRV/c) is reasonable alternative option for patients with existing resistance and/or intolerance to nucleoside reverse transcriptase inhibitors (NRTIs). MATERIAL AND METHODS: All patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and Effectiveness Analysis of Kivexa® (lamivudine/abacavir sulfate) in Human Immunodeficiency Virus Infected Korean Patients
-
Ann H, Lee YS, Kim YS, Jung SI, Lee SH, Lee CS, Lee JS, Choi WS, Choi YH, Kim SW
- KMID: 2450871
- Infect Chemother.
- 2019 Jun;51(2):150-160.
- doi: 10.3947/ic.2019.51.2.150
BACKGROUND: Lamivudine and abacavir sulfate are widely used nucleoside/tide reverse transcriptase inhibitors (NRTI) backbone agents, which are recommended in major international treatment guidelines. The fixed-dose combination of lamivudine and abacavir... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure
-
Lee CI, Kwon SY, Kim JH, Choe WH, Lee CH, Yoon EL, Yeon JE, Byun KS, Kim YS, Kim JH
- KMID: 1774530
- Gut Liver.
- 2014 Jan;8(1):64-69.
BACKGROUND/AIMS: We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies. METHODS: Seventeen patients who failed to achieve... -
- CITED
-
- Close
- SHARE
-
- Close
- Monitoring and Treatment Strategy for Chronic Hepatitis B and Antiviral Resistant Hepatitis B
-
Kim TY, Sohn JH
- KMID: 782870
- Korean J Gastroenterol.
- 2007 Jun;49(6):346-355.
Clinical management of chronic hepatitis B is rapidly evolving after the recent development of new antiviral drugs. These agents have been shown to be effective in improving virological, biochemical, and... -
- CITED
-
- Close
- SHARE
-
- Close
- Current Antiviral Therapy for Chronic Hepatitis B
-
Lim YS, Suh DJ
- KMID: 2157673
- J Korean Med Sci.
- 2004 Aug;19(4):489-494.
- doi: 10.3346/jkms.2004.19.4.489
During the past decade, major breakthroughs have been achieved in treatment of chronic hepatitis B. Currently, three therapeutic agents are approved for chronic hepatitis B: interferon-alpha, lamivudine and adefovir dipivoxil.... -
- CITED
-
- Close
- SHARE
-
- Close
- Development of Clevudine Resistance after Switching from Lamivudine in a Patient with Chronic Hepatitis B
-
Koh KH, Kang CJ, Kim DH, Choi YW, Kim MJ, Cheong JY, Cho SW
- KMID: 783106
- Korean J Gastroenterol.
- 2008 Nov;52(5):325-328.
Clevudine is a nucleoside analog of the unnatural beta-L configuration which has potent antiviral activity against hepatitis B virus (HBV). Clevudine is expected to have similar pattern of resistance profile... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Factors and Clinical Outcome of Viral Breakthrough during Lamivudine Treatment for Chronic Hepatitis B Infection
-
Park NH, Shin JW, Park JH, Bang SJ, Kim DH, Joo KR, Kim DH
- KMID: 1085302
- Korean J Hepatol.
- 2003 Dec;9(4):293-303.
BACKGROUND/AIMS: Long-term treatment with lamivudine causes breakthrough, but the clinical course after lamivudine breakthrough is not well known. The aims of this study were to evaluate the clinical course... -
- CITED
-
- Close
- SHARE
-
- Close
- The Clinical Meaning of the Emergence of Viral Breakthrough during Lamivudine Treatment in Patients with Hepatitis B Virus Related Chronic Liver Disease
-
Park CB, Lim HJ, Yun BC, Lee SU, Han BH
- KMID: 760538
- Korean J Hepatol.
- 2004 Jun;10(2):108-116.
BACKGROUND/AIMS: Viral breakthrough has been considered a major limitation of lamivudine in the treatment of hepatitis B virus related chronic liver disease. Its clinical meaning has not been thoroughly... -
- CITED
-
- Close
- SHARE
-
- Close
- Detection of YMDD Motif Mutants by Oligonucleotide Chips in Lamivudine-Untreated Patients with Chronic Hepatitis B Virus Infection
-
Heo J, Cho M, Kim HH, Shin YM, Jang HJ, Park HK, Kim CM, Kim GH, Kang DH, Song GA, Yang US
- KMID: 2157683
- J Korean Med Sci.
- 2004 Aug;19(4):541-546.
- doi: 10.3346/jkms.2004.19.4.541
Lamivudine, a nucleoside analogue, has been used widely as an effective antiviral agent for the treatment of patients with chronic hepatitis B virus (HBV) infection. However, the YMDD motif mutation... -
- CITED
-
- Close
- SHARE
-
- Close
- Therapeutic Effect of Adefovir Dipivoxil on Recurrent or de novo Infection of Hepatitis B Virus after Liver Transplantation: A Preliminary Report
-
Kim KK, Kim KH, Hwang S, Ahn CS, Moon DB, Ha TY, Lee SG
- KMID: 1767493
- Korean J Gastroenterol.
- 2005 Mar;45(3):174-180.
BACKGROUND/AIMS: Anti-viral therapy using hepatitis B immune globulin and lamivudine could not prevent HBV recurrence after liver transplantation (LT) completely. Adefovir dipivoxil is a acyclic nucleotide phosphate analogue and known... -
- CITED
-
- Close
- SHARE
-
- Close
- The Prophylactic Use of Lamivudine Can Maintain Dose-Intensity of Adriamycin in Hepatitis-B Surface Antigen (HBs Ag)-positive Patients with Non-Hodgkin's Lymphoma Who Receive Cytotoxic Chemotherapy
-
Lee GW, Ryu MH, Lee JL, Oh S, Kim E, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Kim WK, Lee JS, Kang YK
- KMID: 1086742
- J Korean Med Sci.
- 2003 Dec;18(6):849-854.
- doi: 10.3346/jkms.2003.18.6.849
We investigated the effectiveness of lamivudine to prevent hepatitis flare up due to reactivation of hepatitis-B virus (HBV) in hepatitis-B surface antigen (HBsAg)-positive patients with Non-Hodgkin's lymphoma (NHL) during cytotoxic... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcomes after Discontinuation of Lamivudine in Chronic Hepatitis B Patients with Lamivudine Resistant HBV Mutant
-
Kim JK, Hwang SG, Park H, Choi HY, Cho HJ, Ko KH, Hong SP, Park PW, Kim NK, Rim KS
- KMID: 760605
- Korean J Hepatol.
- 2005 Sep;11(3):227-242.
BACKGROUND/AIMS: The therapeutic strategies of applying adefovir for treating lamivudine resistant HBV mutants are controversial. Thus, we observed the clinical outcomes after discontinuation of lamivudine to establish the timing... -
- CITED
-
- Close
- SHARE
-
- Close
